Addus HomeCare (ADUS) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADUS shares.
View ADUS analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month target prices for Addus HomeCare's shares. Their ADUS share price forecasts range from $105.00 to $118.00. On average, they predict the company's share price to reach $110.50 in the next year. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for ADUS or view top-rated stocks among Wall Street analysts.

Addus HomeCare's stock was trading at $99.49 at the start of the year. Since then, ADUS stock has decreased by 13.8% and is now trading at $85.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our ADUS earnings forecast.

Addus HomeCare Co. (NASDAQ:ADUS) announced its quarterly earnings data on Monday, July, 31st. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.07. The business earned $259.98 million during the quarter, compared to analyst estimates of $255.56 million. Addus HomeCare had a net margin of 5.39% and a trailing twelve-month return on equity of 9.06%.

ETFs with the largest weight of Addus HomeCare (NASDAQ:ADUS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Argent Mid Cap ETF (AMID), Invesco S&P SmallCap Health Care ETF (PSCH) and BNY Mellon Women's Opportunities ETF (BKWO).iShares U.S. Healthcare Providers ETF (IHF).

91 employees have rated Addus HomeCare Chief Executive Officer Dirk Allison on Glassdoor.com. Dirk Allison has an approval rating of 51% among the company's employees. This puts Dirk Allison in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Addus HomeCare investors own include AbbVie (ABBV), Bank of America (BAC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Verizon Communications (VZ), CVS Health (CVS), Pfizer (PFE), Ulta Beauty (ULTA), Cisco Systems (CSCO) and Walt Disney (DIS).

Addus HomeCare trades on the NASDAQ under the ticker symbol "ADUS."

Addus HomeCare's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.88%), Silvercrest Asset Management Group LLC (4.33%), Dimensional Fund Advisors LP (4.05%), Principal Financial Group Inc. (3.94%), State Street Corp (3.49%) and WCM Investment Management LLC (3.17%). Insiders that own company stock include Brian Poff, Darby Anderson, David W Tucker, Esteban Lopez, Laurie Manning, Mark L First, Michael D Wattenbarger, R Dirk Allison, Roberton James Stevenson, Sean Gaffney and W Bradley Bickham.
View institutional ownership trends.

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADUS stock can currently be purchased for approximately $85.72.

Addus HomeCare (NASDAQ:ADUS) has a market capitalization of $1.39 billion and generates $951.12 million in revenue each year. The company earns $46.03 million in net income (profit) each year or $3.31 on an earnings per share basis.

The company employs 33,182 workers across the globe.

Addus HomeCare's mailing address is 6801 GAYLORD PARKWAY, FRISCO TX, 75034. The official website for the company is www.addus.com. The company can be reached via phone at (469) 535-8200, via email at investorrelations@addus.com, or via fax at 630-487-2707.